Moore Law PLLC Investigates Claims Against Aardvark Therapeutics, Inc. Following Stock Price Plummet

Investigating Aardvark Therapeutics: Claims of Misleading Safety Data

Moore Law PLLC, a shareholder litigation firm based on Wall Street, has embarked on an investigation into potential claims against Aardvark Therapeutics, Inc., commonly referred to by its NASDAQ ticker AARD. This inquiry comes in light of significant developments involving the biopharmaceutical company, particularly regarding its lead drug candidate ARD-101, which aims to address metabolic diseases.

The heart of the matter revolves around allegations that Aardvark Therapeutics may have overpromised the safety and clinical effectiveness of ARD-101. It has been claimed that executives of the company misrepresented the drug's safety during trials and alleged that it had a minimal risk of serious side effects. Such assertions, if proven, could hold serious implications for the company and its officers.

On February 27, 2026, Aardvark Therapeutics shocked investors when it announced a pause in its Phase 3 HERO trial, following concerning cardiac observations noted during a study with healthy volunteers. This announcement led to a severe downturn in the company's share price, which plummeted by $7.02, marking a staggering 56.2% drop to close at $5.47 by March 2, 2026. Further distress was added when, on May 14, the FDA imposed a complete clinical hold on the testing of ARD-101, resulting in an additional decline of $2.16, or approximately 32.1%, with shares closing at $4.57 the next day.

Given these troubling developments, shareholders of Aardvark Therapeutics who feel impacted or misled are highly encouraged to reach out to Moore Law PLLC. Fletcher Moore, a legal representative from the firm, can be contacted via email at [email protected] Shareholders might have the opportunity to seek not only monetary damages but also reforms within the company's corporate governance. Notably, the representation from Moore Law PLLC operates on a contingency fee basis, meaning that shareholders do not incur any fees unless they succeed in their claims.

In this precarious situation, the focus of Moore Law PLLC's investigation centers on whether there has been any misconduct by Aardvark’s leadership that has affected investors. Shareholders must remain vigilant and proactive in addressing concerns around their investments, especially when they perceive potential injustices stemming from corporate actions.

For those involved or interested in the betterment of shareholder rights and corporate transparency, this ongoing investigation exemplifies the importance of holding corporate executives accountable for their actions. As the inquiry unfolds, it will be essential to monitor further announcements from Aardvark Therapeutics as well as additional updates from Moore Law PLLC regarding this developing situation.

This investigation is a crucial reminder of the larger implications that corporate governance and communication can have on shareholder trust and investment stability. Therefore, those with interests in Aardvark Therapeutics and the larger pharmaceutical sector should stay informed and engaged with the unfolding narrative.